Wellington Management Group LLP Purchases 3,349,244 Shares of Taysha Gene Therapies, Inc. $TSHA

Wellington Management Group LLP raised its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 534.7% during the second quarter, HoldingsChannel.com reports. The firm owned 3,975,605 shares of the company’s stock after buying an additional 3,349,244 shares during the period. Wellington Management Group LLP’s holdings in Taysha Gene Therapies were worth $27,074,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Marex Group plc purchased a new stake in Taysha Gene Therapies in the second quarter valued at about $29,000. E Fund Management Co. Ltd. acquired a new stake in Taysha Gene Therapies in the second quarter worth about $31,000. Tower Research Capital LLC TRC grew its stake in shares of Taysha Gene Therapies by 156.5% during the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock worth $41,000 after acquiring an additional 10,742 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in shares of Taysha Gene Therapies by 143.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock valued at $43,000 after acquiring an additional 4,607 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in shares of Taysha Gene Therapies by 51.9% during the second quarter. BNP Paribas Financial Markets now owns 18,591 shares of the company’s stock valued at $43,000 after acquiring an additional 6,350 shares in the last quarter. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Trading Up 0.5%

Shares of Taysha Gene Therapies stock opened at $5.60 on Friday. The company has a current ratio of 17.76, a quick ratio of 17.76 and a debt-to-equity ratio of 0.13. Taysha Gene Therapies, Inc. has a twelve month low of $2.71 and a twelve month high of $7.30. The firm has a market capitalization of $1.82 billion, a PE ratio of -13.33 and a beta of 1.19. The firm’s 50-day moving average price is $6.06 and its 200 day moving average price is $5.63.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, sell-side analysts predict that Taysha Gene Therapies, Inc. will post -0.52 EPS for the current fiscal year.

Analysts Set New Price Targets

TSHA has been the subject of a number of research analyst reports. Pivotal Research set a $14.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, June 23rd. Robert W. Baird raised their target price on Taysha Gene Therapies from $12.00 to $15.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 30th. Wall Street Zen cut Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Citigroup reiterated an “outperform” rating on shares of Taysha Gene Therapies in a research note on Tuesday, June 23rd. Finally, The Goldman Sachs Group raised their price objective on Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $12.77.

Insider Transactions at Taysha Gene Therapies

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $6.24, for a total value of $1,248,000.00. Following the completion of the sale, the insider directly owned 936,410 shares of the company’s stock, valued at $5,843,198.40. This trade represents a 17.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.48% of the stock is currently owned by insiders.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.